Chrome Extension
WeChat Mini Program
Use on ChatGLM

P 46 Effects of repetitive neuromuscular magnetic stimulation targeting to the upper trapezius muscles in children with headache disorders

C. Börner, J. Staisch, A. Hauser, M. Lang, M. Frohnmüller,I. Hannibal,K. Huß, S. Kruse,B. Klose,M.F. Lechner,N. Sollmann,M.N. Landgraf,F. Heinen,M.V. Bonfert

Clinical Neurophysiology(2022)

Cited 0|Views3
No score
Abstract
Question To assess clinical and muscular effects of a repetitive neuromuscular magnetic stimulation (rNMS) intervention targeting to the upper trapezius muscles (UTM) in pediatric patients with headache disorders. Methods A retrospective chart review resulted in 23 patients with migraine, migraine + tension-type headache (TTH), or post-traumatic headache (PTH), who received 28 rNMS interventions in a pediatric headache center. During 6 sessions, rNMS was delivered to UTM bilaterally (duration: 15min/side, frequency: 20 Hz, 7s ON-time, 10s OFF-time). Headache frequency, duration, and intensity 3 months before and after treatment were recorded using a customized standardized questionnaire prior to the first treatment and at follow-up (FU). We categorized patients into responder classes based on the relative reduction in headache frequency (≥25%, ≥50%, ≥75%). Effects on the muscular level were assessed by pressure pain thresholds (PPTs) above the UTM before, during rNMS treatment, and at FU after 4 to 20 weeks. Results Data from 20 patients were analyzed (14.10 ± 2.69 years; 60% females) as 2 patients were lost to FU and data of 1 patient was classified as outlier based on a late FU (3 SDs above mean FU time) and excluded from analysis. Compared to baseline, headache frequency (p=.017) and minimum and maximum headache intensities (p=.017; p=.023) were significantly reduced at FU. 11 patients (44%) were classified as ≥25% responders, with 7 patients (28%) experiencing a ≥75% reduction of monthly headache days. PPTs above the UTM significantly increased from baseline (left lateral: 2.00 ± 1.37, left medial: 1.96 ± 1.27, right medial: 1.83 ± 1.26, right lateral: 1.94 ± 1.37) to the last treatment session (left lateral: 3.28 ± 2.21, left medial: 3.17 ± 1.99, right medial: 3.17 ± 2.06, right lateral: 3.24 ± 2.25) (left lateral: p=.002, left medial: p=.002, right medial: p=.001, right lateral: p=.003). This increase from baseline sustains until FU (left lateral: 2.87 ± 2.11, left medial: 2.95 ± 2.11, right medial: 2.95 ± 2.11, right lateral: 2.81 ± 2.04) (left lateral: p=.047, left medial: p=.012, right medial: p=.002, right lateral: p=.028). After 14 rNMS interventions in the primary headache group, 6 patients (43%) were classified as ≥25% responders, with 2 patients (14%) experiencing a ≥75% reduction of monthly headache days. After 11 rNMS interventions in the PTH group, 5 patients (46%) were classified as ≥25% responders, with 5 patients (46%) experiencing a ≥75% reduction of monthly headache days. Conclusion Beneficial effects regarding headache characteristics and muscular PPTs were documented in pediatric patients with headache disorders. The latter having a sustained effect up to weeks to months. Based on the concept of the trigemino-cervical complex, rNMS of the UTM may act via neuromodulation of nociceptive processing at the central level.
More
Translated text
Key words
Migraine Prevention,Nerve Transfer,Migraine
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined